Hydromorphone-OROS formulation. - Wikidata - awgldk - TriplyDB

Hydromorphone-OROS formulation.

Hydromorphone-OROS formulation.

http://www.wikidata.org/entity/Q37733564

about

Once-Daily OROS Hydromorphone for Management of Cancer Pain: an Open-Label, Multi-Center, Non-Interventional Study.

P2860

Q37404917-4378BC9A-724C-4768-9961-13052FA2E737

P2860

Hydromorphone-OROS formulation.

http://www.wikidata.org/entity/Q37733564

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on May 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Hydromorphone-OROS formulation.

@en

Hydromorphone-OROS formulation.

@nl

type

label

Hydromorphone-OROS formulation.

@en

Hydromorphone-OROS formulation.

@nl

prefLabel

Hydromorphone-OROS formulation.

@en

Hydromorphone-OROS formulation.

@nl

P1433

Q37733564-A3ED6AB9-C099-4250-B7EB-2673D76A2120

P1476

Q37733564-9A6723EF-083F-4EF3-86E1-C21F3C66313C

P2093

Q37733564-8A64BF0A-D0CB-4E6D-8DD9-B72D67E583A1

P2860

Q37733564-006ACAE7-4BD8-4C66-B26F-398F4E493BD1

Q37733564-05E19BC7-CB8F-4ED1-ACAF-333DED92DB82

Q37733564-2E31364C-F978-49D7-958A-66668D467F01

Q37733564-35EB76EB-A6C5-42AD-B5B9-5C1D5867DBE1

Q37733564-51D060F3-4230-4415-812D-16B9D9B06939

Q37733564-5AAB10B2-08DD-48B2-9184-09EA7667341F

Q37733564-6B5B4B68-2421-4F90-9BCB-D530E7B61213

Q37733564-7DABBA0B-26DF-4800-8EF0-F96177FE7CB5

Q37733564-89796C0A-7A0B-4A8D-B9B2-A106F4B70585

Q37733564-8B5F23C7-A357-4BAD-9838-1D034D9C1F4B

P304

Q37733564-74C64441-3C7C-4AEC-A82A-0D6103DF4AD9

P31

Q37733564-4B01F12C-6597-467A-A517-2AC946782AFB

P356

Q37733564-11043298-43D0-407F-BBA0-9CF57AA4D38D

P407

Q37733564-1FD038D3-E9CA-4B45-9B9C-B6A5B742CA70

P433

Q37733564-47C7EF7E-C2C1-4B05-A433-18CF050B6285

P478

Q37733564-FF6A3A8D-BB6E-4353-A320-1248E1A27FB4

P577

Q37733564-7B32DB53-EA63-4935-8361-57A305AB2966

P698

Q37733564-A4037201-8D88-4C64-B014-2B09FE8B3A52

P356

14656566.2010.482099

P1433

Expert Opinion on Pharmacotherapy

P1476

Hydromorphone-OROS formulation.

@en

P2093

Harold W Goforth

http://www.w3.org/2001/XMLSchema#string

P2860

A randomized, double-blind comparison of OROS(R) hydromorphone and controlled-release morphine for the control of chronic cancer pain.

An open-label, 1-year extension study of the long-term safety and efficacy of once-daily OROS(R) hydromorphone in patients with chronic cancer pain.

Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain.

Chronic opioid therapy for non-cancer pain.

The epidemiology of pain in elderly people.

Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphon

Once-daily OROS hydromorphone for the management of chronic nonmalignant pain: a dose-conversion and titration study

Prevalence of pain in patients with cancer: a systematic review of the past 40 years.

The role of OROS hydromorphone in the management of cancer pain.

The pharmacokinetics of a long-acting OROS hydromorphone formulation.

P304

1207-1214

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14656566.2010.482099

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2010-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20402557

http://www.w3.org/2001/XMLSchema#string